MDL 105519

Known as: MDL 105,519, MDL-105519 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2009
0119962009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Many N-methyl-d-aspartate (NMDA) antagonists produce phencyclidine (PCP)-like side effects that limit their clinical utility… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2005
2005
The present study focused on the role of peripheral ionotropic N-methyl-D-aspartate (NMDA) receptors in the development of… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2004
2004
Molecular models of the ligand-binding domain of N-methyl-d-aspartate subunit R1 (NR1) were made using the published crystal… (More)
Is this relevant?
2002
2002
In an investigation of the mechanisms of the neuroprotective effects of theanine (gamma-glutamylethylamide) in brain ischemia… (More)
  • table 1
Is this relevant?
2001
2001
The use of trifluoroperazine in a well washed rat brain membrane preparation revealed [(3)H]ifenprodil binding to a single high… (More)
Is this relevant?
1997
1997
MDL 105,519, (E)-3-(2-phenyl-2-carboxyethenyl)-4,6-dichloro-1 H-indole-2-carboxylic acid, is a potent and selective inhibitor of… (More)
Is this relevant?
1996
1996
MDL 105,519 [(E)-3-(2-phenyl-2-carboxyethenyl)-4, 6-dichloro-1H-indole-2-carboxylic acid] is a potent ligand at the N-methyl-D… (More)
Is this relevant?